Two decades of hepatitis B vaccination in mentally retarded patients: Effectiveness, antibody persistence and duration of immune memory

Vaccine

Volumn 30, Issue 32, 2012, Pages 4757-4761

  Braeckman, Tessa ^a   Van Herck, Koen ^a,b,c   Jilg, Wolfgang ^d   Bauer, Tanja ^d   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cellular immunity; Effectiveness; Hepatitis B virus; Humoral immunity; Immune memory; Immunization

Indexed keywords

GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; RECOMBINANT HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; FEMALE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MENTAL DEFICIENCY; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

ADULT; AGED; B-LYMPHOCYTES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INSTITUTIONALIZATION; MALE; MENTALLY DISABLED PERSONS; MIDDLE AGED; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84862562778     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.044     Document Type: Article

References (20)

1. Mast E., Mahoney F., Kane M., Margolis H.S., Hepatitis B. Vaccine. Vaccines 2004, 299-337. W.B. Saunders Company, Philadelphia. S. Plotkin, W.A. Orenstein (Eds.).
2. Blumberg B.S., Gerstley B.J., Hungerford D.A., London W.T., Sutnick A.I. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967, 66(5):924-931.
3. Szmuness W., Prince A.M. The epidemiology of serum hepatitis (SH) infections: a controlled study in two closed institutions. Am J Epidemiol 1971, 94(6):585-595. [Epub ahead of print; 1 December 1971].
4. Kingham J.G., McGuire M., Paine D.H., Wright R. Hepatitis, B in a hospital for the mentally subnormal in southern England. Br Med J 1978, 2(6137):594-596. [Epub ahead of print; 26 August 1978].
5. Chaudhary R.K., Perry E., Cleary T.E. Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol 1977, 105(2):123-126.
6. Van Damme P., Cramm M., Van der Auwera J.C., Vranckx R., Meheus A. Horizontal transmission of hepatitis B virus. Lancet 1995, 345(8941):27-29.
7. Coutinho R. Virale hepatitis. Tijdschr Soc Gezondheidszorg 1984, 62:228-232.
8. Reniers J. Hepatitis B in instellingen voor mentaal gehandicapten. Tijdschr Soc Gezondheidszorg 1985, 63:749-754.
9. Van Damme P., Vranckx R., Safary A., Andre F.E., Meheus A. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am J Med 1989, 87(3A):26S-29S. [Epub ahead of print; 4 September 1989].
10. Van Damme P., Vranckx R., Safary A., Andre F.E., Meheus A. Immunogenicity and efficacy of recombinant DNA hepatitis B vaccine in institutionalised mentally retarded patient: preliminary results. Viral hepatitis and liver disease 1988, 1065-1067. Alan R. Liss Inc., New York. A.J. Zuckerman (Ed.).
11. Van Damme P., Meheus A., Vranckx R., Safary A., Andre F. Vaccination of mentally handicapped with a recombinant hepatitis B vaccine: 3 year follow-up. Progress in hepatitis B immunization 1990, 147-156. Colloque INSERM/John Libbey Eurotext Ltd., Paris. P. Coursaget, M.J. Tong (Eds.).
12. Vellinga A., Van Damme P., Weyler J.J., Vranckx R., Meheus A. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine 1999, 17(6):602-606. [Epub ahead of print; 13 March 1999].
13. Vellinga A., Van Damme P., Meheus A. Hepatitis B and C in institutions for individuals with intellectual disability. J Intellect Disabil Res 1999, 43(Pt 6):445-453.
14. Vellinga A., Van Damme P., Bruckers L., Weyler J.J., Molenberghs G., Meheus A. Modelling long-term persistence of hepatitis B antibodies after vaccination. J Med Virol 1999, 57(2):100-103. [Epub ahead of print 19 January 1999].
15. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24(5):572-577. [Epub ahead of print 21 September 2005].
16. Chaves S.S., Fischer G., Groeger J., Patel P.R., Thompson N.D., Teshale E.H., et al. Persistence of long-term immunity to hepatitis B among adolescents immunized at birth. Vaccine 2012, 30(9):1644-1649. [Epub ahead of print 17 January 2012].
17. Zhu C.L., Liu P., Chen T., Ni Z., Lu L.L., Huang F., et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011, 29(44):7835-7841. [Epub ahead of print; 6 August 2011].
18. Leuridan E., Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011, 53(1):68-75. [Epub ahead of print; 10 June 2011].
19. Wenzel J.J., Jilg W. Loss of antibodies, but not of protection. Lancet Infect Dis 2010, 10(11):738-739. [Epub ahead of print; 30 October 2010].
20. Zanetti A.R., Romano L., Giambi C., Pavan A., Carnelli V., Baitelli G., et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010, 10(11):755-761. [Epub ahead of print; 5 October 2010].